While it is recognized that high quality biospecimens are critical in every aspect of today's medicine, the true cost and economic impact of biobanking has been poorly understood and better definition is needed. Current and future initiatives to address this will be discussed and evaluated. Topics will include: the total life cost of ownership, the costs associated with implementing best practices, how can the value of specimens and data be determined, and how can the economic benefits of biobanking be quantified.